Dave Bautista recently commented on the possibility of his return as Drax the Destroyer in Guardians of the Galaxy 4 in the future. In 2023, Marvel Studios’ Guardians of the Galaxy 3 ended with the ...

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

According to preliminary data, the S&P 500 lost 16.58 points, or 0.28%, to end at 6,051.92 points, while the Nasdaq Composite ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims ...

Gilead KOA Holiday has been recognized with the prestigious KOA ICON Award. This recognition highlights campgrounds that demonstrate exceptional operational excellence, customer satisfaction, and a ...

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing. Gilead had reached an inflection point ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other Billionaire Steve Cohen’s top stock picks. Steve Cohen is one of the most prominent ...

GS-1427 is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...